Compare RH & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RH | IDYA |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.9B |
| IPO Year | 1998 | 2019 |
| Metric | RH | IDYA |
|---|---|---|
| Price | $171.41 | $34.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 14 |
| Target Price | ★ $227.33 | $49.42 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 12-11-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.11 | N/A |
| EPS | ★ 5.52 | N/A |
| Revenue | ★ $3,409,319,000.00 | $214,834,000.00 |
| Revenue This Year | $13.15 | $2,434.86 |
| Revenue Next Year | $10.14 | N/A |
| P/E Ratio | $30.96 | ★ N/A |
| Revenue Growth | 9.74 | ★ 5377.66 |
| 52 Week Low | $123.03 | $13.45 |
| 52 Week High | $455.84 | $37.08 |
| Indicator | RH | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 58.48 | 52.66 |
| Support Level | $151.71 | $33.11 |
| Resistance Level | $181.72 | $34.45 |
| Average True Range (ATR) | 8.94 | 1.38 |
| MACD | 2.60 | -0.31 |
| Stochastic Oscillator | 66.47 | 18.97 |
RH is a luxury furniture and lifestyle retailer operating in the $136 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories including furniture, lighting, textiles, bath, decor, and children and is growing the presence of its hospitality business with 23 restaurant locations, including RH Guesthouse. RH innovates, curates, and integrates products, categories, services, and businesses across channels and brand extensions (RH Modern and Waterworks, for example). RH is fully integrated across channels and is positioned to broaden its addressable market over the next decade via expanding abroad, its World of RH digital platform (highlighting offerings outside of home furnishings), and offerings in architecture, media, and more.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.